Table 2.
Association Between PFS of the 56 Patients with Advanced NSCLC and Baseline Characteristic Subgroups in Univariate Analysis and Multivariate Cox Analysis
| Characteristics | Median PFS (95% CI) |
P (Univariate analysis) |
Multivariate analysis | |
|---|---|---|---|---|
| HR (95% CI) | P | |||
|
Age <65 ≥65 |
6.5 (4.75–8.25) 7.0 (5.12–8.88) |
0.617 |
||
|
ECOG performance status score 0–1 2 |
7.6 (5.36–9.84) 4.8 (3.68–5.92) |
0.009 |
0.64 (0.31–0.88) |
0.019 |
|
Gender Male Female |
6.1 (4.92–7.28) 6.5 (4.57–8.43) |
0.536 |
||
|
Pathological staging IIIb IV |
6.6 (4.75–8.45) 6.1 (4.96–7.24) |
0.512 |
||
|
Smoking status Nonsmoker Former smoker/smoker |
7.0 (5.37–8.63) 6.1 (4.72–7.48) |
0.428 |
||
|
Histological category Adenocarcinoma Squamous cell carcinoma |
6.6 (4.71–8.49) 6.1 (4.89–7.31) |
0.531 |
||
|
Lines of previous treatment First-line Second-line or more |
6.5 (4.92–8.08) 7.0 (5.37–8.63) |
0.613 |
||
|
Presence of brain metastases Yas No |
5.9 (4.67–7.13) 6.6 (4.91–8.29) |
0.339 |
||
|
History of surgical resection Yes No |
7.0 (5.35–8.65) 6.1 (4.93–7.27) |
0.311 |
||
|
EGFR mutation status Positive Negative |
6.1 (4.78–7.42) 6.6 (5.09–8.11) |
0.469 |
||
|
TP53 mutation status Mutation group Rest group |
8.2 (3.21–13.19) 5.5 (3.17–7.84) |
0.216 |
||
|
Number of metastatic lesions ≤3 >3 |
7.0 (5.08–8.92) 5.0 (3.83–6.17) |
0.018 |
0.72 (0.41–0.92) |
0.026 |
|
Initial dosage of anlotinib (mg) 12 10 |
7.0 (5.67–8.33) 5.9 (4.76–7.04) |
0.117 |
||
|
Immunotherapy Camrelizumab Tislelizumab Pembrolizumab Nivolumab |
6.1 (5.04–7.16) 7.0 (5.39–8.61) 6.5 (4.93–8.07) 6.6 (5.21–7.99) |
0.475 |
||